Market Place
Sourcing Support
CG Oncology Closes Public Offering, Full Underwriter Option
16 Dec 2024 //
GLOBENEWSWIRE
CG Oncology Announces Pricing of Public Offering
12 Dec 2024 //
GLOBENEWSWIRE
CG Oncology Announces Proposed Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
SUO-CTC & CG Oncology Launch NMIBC Research Fellowship Award
06 Dec 2024 //
GLOBENEWSWIRE
Cretostimogene Grenadenorepvec Shows Durable Responses in Cancer
05 Dec 2024 //
GLOBENEWSWIRE
CG Oncology To Present Cretostimogene Grenadenorepvec Results At SUO
20 Nov 2024 //
GLOBENEWSWIRE
CG Oncology Reports Q3 2024 Financial Results & Business Updates
12 Nov 2024 //
GLOBENEWSWIRE
CG Oncology Publishes Cretostimogene Data in Nature Medicine
11 Nov 2024 //
GLOBENEWSWIRE
CG Oncology To Attend Morgan Stanley Global Healthcare Conference
30 Aug 2024 //
GLOBENEWSWIRE
CG Oncology Reports Q2 2024 Results And Provides Business Updates
08 Aug 2024 //
GLOBENEWSWIRE
CG Oncology Initiates Expanded Access Program For Cretostimogene Grenadenorepvec
18 Jun 2024 //
GLOBENEWSWIRE
CG Oncology Announces Publication Of CORE-001 Study In Nature Medicine
06 Jun 2024 //
GLOBENEWSWIRE
Cg Bcel-Core-001 Full Results: Cretostimogene + Pembro Positive At Asco24
24 May 2024 //
GLOBENEWSWIRE
CG Oncology Q1 2024 Financials And Business Updates
09 May 2024 //
GLOBENEWSWIRE
CG Oncology sets new bar in bladder cancer, months after huge IPO
04 May 2024 //
FIERCE BIOTECH
Cretostimogene Shows 75.2% Response In Bladder Cancer
03 May 2024 //
GLOBENEWSWIRE
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
26 Apr 2024 //
GLOBENEWSWIRE
CG Oncology Unveils Cretostimogene+Pembrolizumab Results at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
28 Mar 2024 //
GLOBENEWSWIRE
CG Oncology Announces First Patient Dosed in Phase 3 Trial of Cretostimogene
27 Feb 2024 //
GLOBENEWSWIRE
CG Oncology Announces Closing of Initial Public Offering to Purchase Shares
30 Jan 2024 //
BUSINESSWIRE
CG Oncology brings in $380M from first biotech IPO of 2023
25 Jan 2024 //
FIERCE BIOTECH
CG Oncology Announces Pricing of Upsized Initial Public Offering
24 Jan 2024 //
BUSINESSWIRE
Biotech`s 2024 IPO season kicks off with heavy demand for CG Oncology
24 Jan 2024 //
ENDPTS
CG Oncology aims for $209M IPO, as more biotechs eye Nasdaq
18 Jan 2024 //
FIERCE BIOTECH
CG Oncology plans IPO ahead of phase 3 bladder cancer readout
03 Jan 2024 //
FIERCE BIOTECH
CG Oncology files for IPO as biotech market shows signs of a rebound
02 Jan 2024 //
ENDPTS
CG Oncology Receives Fast Track and Breakthrough Designation for Cretostimogene
05 Dec 2023 //
BUSINESSWIRE
CG Oncology Announces Presentation of Data for Cretostimogene Grenadenorepvec
14 Nov 2023 //
BUSINESSWIRE
CG Oncology Announces Key Executive Appointments in Commercialization
05 Sep 2023 //
BUSINESSWIRE
CG Oncology Announces $105 Million Oversubscribed Crossover Financing
02 Aug 2023 //
BUSINESSWIRE
CG raises $105M crossover round to fund phase 3 cancer trial
02 Aug 2023 //
FIERCE BIOTECH
CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study
24 Jul 2023 //
BUSINESSWIRE
CG Oncology Announces New Ph2 Data with Cretostimogene Grenadenorepvec (CG0070)
01 May 2023 //
BUSINESSWIRE
Phase 2 Data With CG0070 in Combination with KEYTRUDA in BCG-Unresponsive NMIBC
10 Apr 2023 //
BUSINESSWIRE
CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
27 Dec 2022 //
BUSINESSWIRE
CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA®
10 Nov 2022 //
BUSINESSWIRE
CG spotlights oncolytic virus combo data ahead of full readout due next year
10 Nov 2022 //
ENDPTS
CG Oncology to Present New Phase 2 Data with CG0070 in Combination with KEYTRUDA
24 Oct 2022 //
BUSINESSWIRE
CG Oncology Presents New Clinical Data on Two Ongoing Programs at ASCO 2022
04 Jun 2022 //
BUSINESSWIRE
CG Oncology Presents Interim Phase 2 Data with CG0070 + KEYTRUDA
13 Apr 2022 //
BUSINESSWIRE
CG Oncology Begins Dosing in Japan in Phase 3 Monotherapy Study of CG0070
20 Dec 2021 //
BUSINESSWIRE
CG Oncology reports Phase II preliminary data on bladder cancer therapy
15 Nov 2021 //
CLINICALTRIALSARENA
CG Oncology Presents Preliminary Ph 2 Data with CG0070 in Combination KEYTRUDA
13 Nov 2021 //
BUSINESSWIRE
CG Oncology to Present Two Programs atSITC) 2021 Annual Meeting
12 Oct 2021 //
BUSINESSWIRE
CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb
09 Sep 2021 //
BUSINESSWIRE
CG Oncology doses first patient in oncolytic immunotherapy trial
10 Dec 2020 //
CLINICALTRIALSARENA
CG Oncology Closes $47 Million Series D Financing
10 Dec 2020 //
BUSINESSWIRE
CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of CG0070
09 Dec 2020 //
BUSINESSWIRE
CG Oncology Announces First Patient Dosed in Ph1b Study of Oncolytic CG0070
12 Nov 2020 //
BUSINESSWIRE
